Industry News
In patients with advanced myelofibrosis, PRM-151 therapy is well tolerated
Dec 12, 2014
A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive... Read More
Study suggests that more-experienced centers have better patient outcomes for head and neck cancer
Dec 12, 2014
When it comes to specialized cancer surgery, it's generally true that the more experienced the surgeon, the better the outcome. Read More
Tamoxifen has reduced breast cancer rates 'by a third'
Dec 12, 2014
A well-established and effective treatment for breast cancer, tamoxifen has now been shown to have long-term preventive benefits for women at high risk. Read More
Protein inhibitor makes toughest breast cancer cell susceptible to chemotherapy
Dec 12, 2014
Triple-negative breast cancer is as bad as it sounds. The cells that form these tumors lack three proteins that would make the cancer respond to powerful, customized treatments. Read More
Some ovarian and breast cancer patients may benefit from manipulation of a non-coding microRNA
Dec 12, 2014
A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers. Read More
Some ovarian and breast cancer patients may benefit from manipulation of a non-coding microRNA
Dec 12, 2014
A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers. Read More
New targeted drugs could treat drug-resistant skin cancer
Dec 11, 2014
A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports. Read More
Getting antibodies into shape to fight cancer
Dec 11, 2014
Scientists at the University of Southampton have found that the precise shape of an antibody makes a big difference to how it can stimulate the body's immune system to fight cancer, paving the way... Read More
Follow-up data from idelalisib (Zydelig) registrational studies in patients with chronic lymphocytic leukaemia and follicular lympho
Dec 11, 2014
Gilead Sciences, Inc. has announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and the safety profile for... Read More
Scottish medicines consortium accepts the use of Alimta (pemetrexed) for maintenance treatment of non-small cell lung cancer
Dec 11, 2014
On 8th December 2014, the Scottish Medicines Consortium accepted for use within NHS Scotland Alimta (pemetrexed) monotherapy for the maintenance treatment of locally advanced or metastatic... Read More
Previous Page Next Page